BBT-301 / CellionBioMed, Bridge Biotherap - LARVOL DELTA

Bridge Bio, returns to Chaperone, a candidate for idiopathic pulmonary fibrosis treatment [Google translation] (Health Korea News) - "Bridge Biotherapeutics is returning the idiopathic pulmonary fibrosis (IPF) treatment candidate it had acquired from Chaperone. Bridge Bio announced on the 10th through a public disclosure that it had decided to terminate the technology acquisition contract for the IPF candidate 'BBT-209' with Chaperone. Chaperone is not obligated to return the 2 billion won advance payment it received from Bridge Bio, and Bridge Bio is not obligated to pay additional interim and current technology royalties to Chaperone....BBT-301 plans to enter global phase 2 clinical trials by submitting a US clinical trial plan (IND) in the second half of next year."

IND • Licensing / partnership • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease

Bridge Bio selected as ‘presenting company’ at 2024 Bio USA for 3 consecutive years [Google translation] (Medipana) - "We plan to share major progress and additional data related to clinical trials. In particular, as the registration of patients in the multinational phase 2 clinical trial of BBT-877 progresses to approximately 75% of the target, discussions on the drug's efficacy and safety are expected to progress further....the company has been selected as a Bio USA presenting company for the third consecutive year and will conduct a company introduction presentation to industry officials and potential partners. In an oral presentation held at 2 pm on the 3rd (local time)...Pavel Printsev will discuss the current status of development of major clinical projects BBT-877 and BBT-207 (non-small cell lung cancer treatment candidates), as well as future expectations. Share key development milestones. In addition, we are preparing a U.S. clinical trial plan (IND) for BBT-301 (a candidate for the treatment of idiopathic pulmonary fibrosis)..."

Clinical • P2 data • Idiopathic Pulmonary Fibrosis • Immunology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Bridge Biotherapeutics Presented Non-clinical Study Results for 2 IPF Candidates at the IPF Summit 2022 (PRNewswire) - "Bridge Biotherapeutics...presented the non-clinical study results of 'BBT-301', a novel, small molecular inhibitor of KCa 3.1, and 'BBT-209', an endogenous GPCR19 agonist, both being developed as novel IPF treatments, at the 6th Annual IPF Summit (August 29 - September 1, 2022), in Boston, MA....BBT-301 also improved pulmonary function, and attenuated Ashcroft and collagen deposition in bleomycin (BLM)-induced animal model...BBT-209 has exhibited competitive inhibitory effects against cytokine expressions such as IL-1β and TNF-α, with EC50 (effective concentration of 50%) of 0.031 and 0.36 μM each."

Preclinical • Idiopathic Pulmonary Fibrosis • Immunology

Bridge Biotherapeutics first announced two new IPF projects at a conference in the US (Asia Times) - "Bridge Biotherapeutics, at the '2022 IPF Summit' held in Boston, USA, conducted major non-clinical trials of 'BBT-301' and 'BBT-209', new idiopathic pulmonary fibrosis (IPF) treatment candidates. It was announced on the 31st that the data was presented in the form of a poster. Bridge Biotherapeutics unveiled for the first time on the international stage non-clinical data related to drug efficacy and efficacy confirmed in cell lines and animal models for two new candidates under development with different mechanisms of action in IPF."

Preclinical • Idiopathic Pulmonary Fibrosis

Bridge Bio to disclose two idiopathic pulmonary fibrosis data at IPF 2022 (Korea Biomedical Review) - "Bridge Biotherapeutics announced that it would release non-clinical data of idiopathic pulmonary fibrosis (IPF) treatment candidates BBT-301 and BBT-209 at the IPF summit 2022 to be held at Boston from Aug. 29 to Sept. 1....Bridge Bio plans to introduce non-clinical trial research data at the IPF 2022 in a poster format as it has conducted diverse non-clinical trial research after optionally adopting the project from Cellion Biomed in March....'We have decided to disclose non-clinical data at the IPF summit as there are increasing interests of our company’s new pipeline due to the U.S. FDA’s approval for BBT-877 phase 2 clinical trial.'"

Clinical data • Preclinical • Idiopathic Pulmonary Fibrosis

Bridge Biotherapeutics Enters into an Option-to-License Agreement with CellionBioMed to Develop BBT-301 for the Treatment of Multiple Fibrotic Diseases (PRNewswire) - "Bridge Biotherapeutics...announced that the company has signed an exclusive option-to-license agreement for CellionBioMed's ion channel modulator (BBT-301), in order to develop a novel therapy for multiple fibrotic diseases including idiopathic pulmonary fibrosis (IPF)....By entering into the option-to-license agreement, Bridge will make an option payment of approximately USD 0.4 million (KRW 500 million). The companies will also conduct joint studies into new therapeutic indications.The potential deal value equates to approximately USD 24 million (KRW 29 billion) including option, upfront, and milestone payments. CellionBioMed is also entitled to receive royalty payments upon the commercialization of BBT-301."

Licensing / partnership • Idiopathic Pulmonary Fibrosis